Evidence map›Paper›PMID 33923753›Full record

ArticleCells2021

The Role of Heparan Sulfate and Neuropilin 2 in VEGFA Signaling in Human Endothelial Tip Cells and Non-Tip Cells during Angiogenesis In Vitro.

Marchien G Dallinga, Yasmin I Habani, Alinda W M Schimmel, Geesje M Dallinga-Thie, Cornelis J F van Noorden, Ingeborg Klaassen, Reinier O Schlingemann

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Marchien G DallingaOcular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Yasmin I HabaniOcular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Alinda W M SchimmelDepartment of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Geesje M Dallinga-ThieDepartment of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0001-5412-5923
Cornelis J F van NoordenOcular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Ingeborg KlaassenOcular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0003-1695-9403
Reinier O SchlingemannOcular Angiogenesis Group, Departments of Ophthalmology and Medical Biology, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLFondation Asile des Aveugles · CHNational Institute of Biology · SI

Funding

Algemene Nederlandse Vereniging Ter Voorkoming Van Bindheid UitZicht2013-12 and UitZicht2018-26E & M Blaauw fonds NALandelijke Stichting voor Blinden en Slechtzienden UitZicht2013-12 and UitZicht2018-26ODAS Stichting UitZicht2013-12 and UitZicht2018-26Rotterdamse Stichting Blindenbelangen B20130006, B20180072Stichting Blindenpenning UitZicht2013-12 and UitZicht2018-26Stichting Nederlands Oogheelkundig Onderzoek Grant 2013-04Stichting tot Verbetering van het Lot der Blinden NA
6 · The paper itself

Abstract

During angiogenesis, vascular endothelial growth factor A (VEGFA) regulates endothelial cell (EC) survival, tip cell formation, and stalk cell proliferation via VEGF receptor 2 (VEGFR2). VEGFR2 can interact with VEGFR2 co-receptors such as heparan sulfate proteoglycans (HSPGs) and neuropilin 2 (NRP2), but the exact roles of these co-receptors, or of sulfatase 2 (SULF2), an enzyme that removes sulfate groups from HSPGs and inhibits HSPG-mediated uptake of very low density lipoprotein (VLDL), in angiogenesis and tip cell biology are unknown. In the present study, we investigated whether the modulation of binding of VEGFA to VEGFR2 by knockdown of

Indexed as

Neovascularization, PhysiologicSignal TransductionApoptosisHeparan SulfateHumansHuman Umbilical Vein Endothelial CellsLipoproteins, VLDLNeuropilin-2SulfatasesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Heparan SulfateLipoproteins, VLDLNeuropilin-2SULF2 protein, humanSulfatasesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2angiogenesisendothelial cellsHSPGNRP2SULF2tip cellsVEGFA

Identifiers

PMID33923753
PMCPMC8073389
OpenAlexW3156118332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.